By [Your Name], Health & Science Correspondent
In the world of biomedical research, where lives hang in the balance and fortunes are spent in pursuit of elusive cures, few voices are as sharply critical—or as urgently needed—as that of Alice Gilman.
A neuroscientist by training and an unflinching critic of the status quo, Gilman has spent years examining the disconnect between the models we use to develop drugs and the realities of human biology. Her message is clear and provocative: we are building medicine on broken foundations.
“Imagine trying to build a rocket to reach orbit by testing miniature fireworks in your backyard,” she told a recent audience of clinicians and researchers. “You can learn something. But confuse that for a full blueprint, and your astronauts are dead the moment the real engines light.”
That metaphor, equal parts vivid and damning, encapsulates Gilman’s growing concern: that the dominant tools of preclinical research—organoids, animal models, and cell cultures—may be teaching us the wrong lessons. Or worse, giving us the illusion of understanding where none exists.
The Rocket Fallacy
Gilman compares modern drug development to launching miniature rockets—rodent studies and isolated tissues that show local truths but fail to scale to the full human system. These models might show how a gene mutation affects a single organ or pathway, but they cannot reflect the complex choreography of metabolism, hormones, immune memory, or aging over decades. The extrapolation is, in her view, fundamentally flawed.
And the costs are not theoretical.
Time and again, therapies that showed promise in mice failed dramatically in human trials. The infamous case of beta-amyloid treatments for Alzheimer’s is a stark example. Despite clearing plaques in genetically engineered mice, these therapies repeatedly failed to help human patients. Stroke drugs, sepsis treatments—many succeeded in rodent models only to collapse in late-stage trials, burning through billions of dollars and years of hope.
“The small rockets flew,” Gilman says. “The real ones exploded.”
When the System Gets Lucky
Yet amid these failures, there are stories of accidental success. GLP-1 agonists—now hailed as a breakthrough in diabetes and obesity—initially showed mixed or dangerous signals in animals. Rodents developed tumors. Metabolic outcomes were inconsistent. Based on model data alone, these drugs should have been shelved. Instead, persistence led to human trials that revealed their true potential: weight loss, cardiovascular benefits, extended life.
To Gilman, this isn’t evidence that the system works—it’s proof that we sometimes get lucky despite it.
A Broken Loop
At the heart of her critique is a simple yet devastating observation: if the model doesn’t match the system, then the scientific method cannot function. Hypotheses can’t be tested. Data can’t be trusted. The feedback loop that makes science self-correcting breaks down.
This has implications far beyond academic frustration. Clinical trial failure rates remain staggeringly high. Hundreds of billions of dollars are lost every year. More critically, nearly 100,000 people die each day from aging and disease, many of them from conditions we might already have treated—if our tools were better.
And yet, Gilman notes, this crisis is accepted as business as usual.
“In aviation, a record like this would cause riots,” she says. “In medicine, we treat it as attrition.”
An Inverted Ethics
Gilman’s work also challenges the ethical frameworks that govern preclinical research. She criticizes the triumphalism around reducing animal testing if the alternative models are equally misleading.
“The suffering doesn’t disappear,” she says. “It’s exported—downstream—to patients in doomed trials, and to people waiting in vain.”
In her view, ethics is not about counting mice. It’s about scientific honesty. It’s about telling the truth.
Fixing the Foundation
Gilman’s vision for reform is not a wholesale rejection of models but a demand for accountability: we must recognize what models can and cannot teach us. We need to develop better systems—ones that reflect human complexity, not just cellular mechanisms. And we must be willing to discard or redesign models when they fail to serve their purpose.
“History will remember whether we chose to repair the foundation of science,” she warns. “If we don’t, disease and time will write our record for us.”
In a field often constrained by inertia and economics, Alice Gilman’s challenge is radical. But for a world desperate for cures that work, it may also be the call we can no longer afford to ignore.